Results 11 to 20 of about 47,802 (187)
Lancet, The, 2015 Frontotemporal dementia is an umbrella clinical term that encompasses a group of neurodegenerative diseases characterised by progressive deficits in behaviour, executive function, or language. Frontotemporal dementia is a common type of dementia, particularly in patients younger than 65 years. The disease can mimic many psychiatric disorders because of
Jee Bang +2 more
exaly +5 more sources
Journal of Geriatric Psychiatry and Neurology, 2016 Frontotemporal dementia (FTD) is a not-uncommon explanation for progressive cognitive deficit in patients who often have a genetic susceptibility for such a neurodegenerative process. However, FTD does not seem to identify one particular pathogenetic mechanism but rather a spectrum of pathologies with particular predilection for the frontal and ...
Tor Rosness, Zeina Chemali
exaly +3 more sources
British Journal of Psychiatry, 2002 BackgroundFrontotemporal dementia accounts for up to 20% of cases of dementia in the presenium, yet remains poorly recognised. Diagnostic criteria have been devised to aid clinical diagnosis.AimsTo provide an overview of clinical and pathological characteristics of frontotemporal dementia and its nosological status.MethodsThe review summarises ...
Neary, David +2 more
openaire +6 more sources
Neurologic Clinics, 2017 Frontotemporal dementia (FTD) is a heterogeneous disorder with distinct clinical phenotypes associated with multiple neuropathologic entities. Presently, the term FTD encompasses clinical disorders that include changes in behavior, language, executive control, and often motor symptoms.
Olney, Nicholas T +2 more
openaire +4 more sources
Frontotemporal Dementias [PDF]
Continuum, 2016 This article reviews the common behavioral and cognitive features of frontotemporal dementia (FTD) and related disorders as well as the distinguishing clinical, genetic, and pathologic features of the most common subtypes.Advances in clinical phenotyping, genetics, and biomarkers have enabled improved predictions of the specific underlying molecular ...
openaire +2 more sources
Treatment of Frontotemporal Dementia [PDF]
Current Treatment Options in Neurology, 2014 Frontotemporal dementia (FTD) encompasses a spectrum of neurodegenerative diseases with heterogeneous clinical presentations and two predominant types of underlying neuropathology. FTD typically comprises three distinct clinical syndromes: behavioral variant frontotemporal dementia (bvFTD), semantic variant primary progressive aphasia (svPPA), and ...
Tsai, Richard M, Boxer, Adam L
openaire +4 more sources
Genetics of Frontotemporal Dementia [PDF]
American Journal of Neuroradiology, 2016 FTD : frontotemporal dementia In 1892, Arnold Pick, a neuropsychiatrist at the University of Prague, made the first description of frontotemporal dementia (FTD). In his case report, “On the relationship between senile atrophy of the brain and aphasia,” he described a 71-year-old man ...
F.W. Rohlfing, R.K. Tu
openaire +4 more sources
Value of MRI Outcomes for Preventive and Early‐Stage Trials in Spinocerebellar Ataxias 1 and 3
Annals of Clinical and Translational Neurology, EarlyView.ABSTRACT Objective To examine the value of MRI outcomes as endpoints for preventive and early‐stage trials of two polyglutamine spinocerebellar ataxias (SCAs). Methods A cohort of 100 participants (23 SCA1, 63 SCA3, median Scale for the Assessment and Rating of Ataxia (SARA) score = 5, 42% preataxic, and 14 gene‐negative controls) was scanned at 3T up ...
Thiago J. R. Rezende +26 more
wiley +1 more source
The epidemiology of frontotemporal dementia [PDF]
International Review of Psychiatry, 2013 Frontotemporal dementia, a heterogeneous neurodegenerative disorder, is a common cause of young onset dementia (i.e. dementia developing in midlife or earlier). The estimated point prevalence is 15-22/100,000, and incidence 2.7-4.1/100,000. Some 25% are late-life onset cases.
Chiadi U, Onyike, Janine, Diehl-Schmid
openaire +2 more sources
Fluid Biomarkers of Disease Burden and Cognitive Dysfunction in Progressive Supranuclear Palsy
Annals of Clinical and Translational Neurology, EarlyView.ABSTRACT Objective Identifying objective biomarkers for progressive supranuclear palsy (PSP) is crucial to improving diagnosis and establishing clinical trial and treatment endpoints. This study evaluated fluid biomarkers in PSP versus controls and their associations with regional 18F‐PI‐2620 tau‐PET, clinical, and cognitive outcomes.
Roxane Dilcher +10 more
wiley +1 more source